Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab dosing regimens in plaque psoriasis
NCT02513550Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in plaque psoriasis (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Static Physician Global Assessment (0,1) at 52 weeks and Psoriasis Area and Severity Index 75 at 52 weeks. Started Aug 2015; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02513550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513550.